TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03706326

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-MUC1 CAR-T cells
Description: Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 knockout Engineered T cells
Description: Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CAR-T combined with PD-1 Knockout T cells
Description: Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
Study: NCT02386566

Intervention type: DRUG
Intervention: natalizumab
Description: As described in the treatment arm
Study: NCT01729416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Exchange Colonoscopy
Description: We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air Colonoscopy
Description: Air will be infused into the colon during colonoscopy.
Study: NCT01813799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 300mg
Description: 300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 600mg
Description: 600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
Study: NCT04320459

Intervention type: DIAGNOSTIC_TEST
Intervention: Toronto Alexithymia Scale-20 (TAS-20)
Description: It assess alexithymia. It is a 20 item questionnaire and each item is evaluated in a Likert type scale with five intervals (1= strongly disagree, 5=strongly agree). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck's Depression Inventory (BDI)
Description: It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Beck's Depression Inventory (BDI)
Description: It assess depression status. It is a 21-question multiple-choice self-report inventory, each set is ranked in terms of severity and scored from 0 to 3 with a total summed score range of 0-63. Higher scores indicate greater depressive severity. Conventional cutoffs are 0-9 for normal range, 10-18 for mild to moderate depression, 19-29 for moderate to severe depression, and 30-63 for severe depression.
Study: NCT02533999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK® Plasma System
Description: Surgical method for tonsillectomy and adenoidectomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrosurgery
Description: Surgical method for tonsillectomy and adenoidectomy.
Study: NCT02057952

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and exercise
Description: The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and exercise
Description: The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
Study: NCT02963298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous renal replacement therapy
Study: NCT02797964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRA737
Description: SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
Study: NCT00680576

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT, Cognitive Behavioral Therapy
Description: Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FFT, Family Functional Therapy
Description: Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
Study: NCT02638857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: TACE
Description: lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell
Description: DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipiodol
Description: lipiodol 10-20ml,hepatic arterial infusion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: lipiodol
Description: lipiodol 10-20ml,hepatic arterial infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin (MMC)
Description: MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mitomycin (MMC)
Description: MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin(EADM)
Description: EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Epirubicin(EADM)
Description: EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Precision Multiple Antigen T Cell
Description: PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
Study: NCT02376985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral management

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT00446264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: islet transplantation
Description: Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab - sirolimus - tacrolimus
Description: Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
Study: NCT02140164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
Study: NCT01724398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional plus UC-MSC treatment
Description: Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional plus PE treatment
Description: Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional plus UC-MSC and PE therapy
Description: Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
Study: NCT04663880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to placebo in EEC
Description: Patients are exposed to placebo (saline solution) in the EEC for 4h maximum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to placebo in EEC
Description: Patients are exposed to placebo (saline solution) in the EEC for 4h maximum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to three concentrations of HDM allergen in EEC
Description: Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to a single concentration of HDM allergen in EEC
Description: Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum
Study: NCT01166854

Intervention type: DEVICE
Intervention: Diffuse Optical Spectroscopy
Description: Diffuse Optical Spectroscopy
Study: NCT03299530

Intervention type: OTHER
Intervention: patients with corneal astigmatism
Description: The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
Study: NCT01254045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: intranasal placebo (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: intranasal placebo (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: intranasal placebo (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: intranasal placebo (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: intranasal placebo (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: intranasal placebo (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 24IU
Description: intranasal oxytocin (24 international units) and intranasal placebo (24 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 24IU
Description: intranasal oxytocin (24 international units) and intranasal placebo (24 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 24IU
Description: intranasal oxytocin (24 international units) and intranasal placebo (24 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 24IU
Description: intranasal oxytocin (24 international units) and intranasal placebo (24 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 24IU
Description: intranasal oxytocin (24 international units) and intranasal placebo (24 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 24IU
Description: intranasal oxytocin (24 international units) and intranasal placebo (24 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 48IU
Description: intranasal oxytocin (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 48IU
Description: intranasal oxytocin (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 48IU
Description: intranasal oxytocin (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 48IU
Description: intranasal oxytocin (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 48IU
Description: intranasal oxytocin (48 international units)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin 48IU
Description: intranasal oxytocin (48 international units)
Study: NCT02110706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will receive a vehicle control infusion
Study: NCT01423838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: 5 mg, oral, once in a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: 5 mg, oral, three times in a day
Study: NCT03501784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nobio particles incorporated within Novidia Dental Bonding
Description: Nobio particles incorporated within Novidia Dental Bonding and Flow

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek bond and flow composite
Description: standard of care class V composite restoration performed with Filtek and 3M
Study: NCT02891265

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking cessation patch
Description: To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
Study: NCT05071547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered acceptance and commitment therapy (ACT)
Description: ACT builds on cognitive behavioral therapy (CBT), and includes methods for experiential learning and focus on psychological flexibility

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary Pain Rehabilitation Program (IPRP)
Description: Multimodal treatment where physio therapists, occupational therapists, psychologists and physicians give synchronized treatments to raise physical and psychological function and promote return to work
Study: NCT03334487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Intravenous
Study: NCT01324245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenoldopam
Description: Intravenous infusion at 0.5 mics/Kg/min for three hours
Study: NCT01583751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videoendoscopic resection of pilonidal sinus
Description: Resection of pilonidal sinus tissue with videoendoscopic approach.
Study: NCT03230032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pacifier-activated device
Description: The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
Study: NCT02468661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280 single agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INC280 single agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Study: NCT00629486

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polymorphism of IL-1 beta and TNF-alpha
Description: To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
Study: NCT01813799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9801 900mg
Description: 900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
Study: NCT00689403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended release capsules, oral single doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Extended release capsules, oral single doses
Study: NCT02741271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MF MDI 100 mcg BID (Open Label)
Description: Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF MDI 100 mcg BID (Open Label)
Description: Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF/F MDI 100/10 mcg BID
Description: After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MF MDI 100 mcg BID
Description: After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/Salbutamol PRN
Description: Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
Study: NCT05997004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: After surgical creation of umbilical port Control group received injection normal saline 1ml.
Study: NCT02741271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol PRN
Description: Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone/Prednisolone
Description: Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone
Description: Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
Study: NCT01502345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine/device combination for prevention of HFRS
Description: PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine/device combination for prevention of HFRS
Description: PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine/device combination for prevention of HFRS
Description: PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
Study: NCT02241681

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Peptamen 1.5
Description: Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
Study: NCT05997004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: After surgical creation of umbilical port Group II received injection Glycopyrrolate 1ml=0.2mg
Study: NCT01436994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Block and Replace
Description: The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
Study: NCT01720940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous vancomycin infusion
Description: 24-hour continuous infusion of vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent vancomycin infusion
Study: NCT00520351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClearCare
Description: contact lens care system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optifree Replenish
Description: contact lens care system
Study: NCT01597895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: Maraviroc 150 mg BID x 5 days with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Boceprevir
Description: Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc + Telaprevir
Description: Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food